HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.
This study provides further evidence that gastric H. pylori is involved in the physiologic regulation of these hormones, and supports the rationale for randomized controlled H. pylori eradication trials to focus on the role of inflammation and endocrine cross-talk in explaining these findings.
The Helicobacter Eradication Aspirin Trial (HEAT) is a National Institute of Health Research-funded, double-blind placebo controlled randomised trial of the effects of H. pylori eradication on subsequent ulcer bleeding in infected individuals taking aspirin daily, conducted in practices across the whole of England, Wales and Northern Ireland.
While there are conflicting data on the role of H. pylori as a risk factor for UGICs with low-dose aspirin [ 69, 70], the ongoing large-scale outcomes study Helicobacter Eradication Aspirin Trial (HEAT; ClinicalTrials.gov identifier NCT01506986) promises to provide more definitive information on the relationship between H. pylori infection and GI bleeding during aspirin use.
In patients participating in the before mentioned H. pylori eradication in NSAID users trial, we measured H. pylori IgG-antibody titers and titer changes in order to diagnose successful H. pylori eradication [ 29].
From 1996 to 1998, 10,537 individuals, aged 20 59 years, registered with seven general practices in Southwest England were enrolled in a community based randomised controlled trial of eradication of Helicobacter pylori (H. pylori).
In a cross-sectional community based study, as part of a randomised controlled trial of eradication of Helicobacter pylori infection, the association between blood pressure and symptoms of gastro-oesophageal reflux was examined.
W.-C. Tai et al. in "Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication" conducted a prospective trial to compare the efficacies of nonbismuth containing quadruple therapy and standard triple therapy in Taiwan.
However, in our trial, the eradication rate of sequential therapy did not reach the good category according to the Graham's report card for grading H. pylori therapy [ 32] (90–95 % intention-to-treat) as with most other studies [ 15, 33, 34] and did not demonstrate a significant difference compared to triple therapy.
